StreetAlpha.app
Home › Stocks › DSGN

Design Therapeutics, Inc. (DSGN)

Healthcare
$9.02
▼ −3.22%
LAST CLOSE · NOV 20

Design Therapeutics develops GeneTAC small molecule drug candidates for inherited diseases caused by repeated gene sequences. It last closed at $9.02 on Nov 20, down 3.22% on the day. The next earnings report for DSGN is expected around Mon, Mar 8, 2027, after the close. For the quarter ended Sep 2026, DSGN reported EPS of -$0.32 on revenue of $0. Over its last 8 reports the stock moved an average of 7.5% the session after earnings.

AI Auto Pilots
Is DSGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DSGN.

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$74.1M
EPS (diluted)
−$1.20
Free cash flow
−$59.4M
Valuation
Market cap
$577.6M
64.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$15.3M
At Sep 30
Shareholder equity
$202.2M
Shares outstanding
64.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $0$0FY2025

From DSGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 8
Estimated date · After the close
Reported EPS
-$0.32
Quarter ended Sep 2026
Year ago EPS
-$0.30
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.24Dec '24Mar 2025: -$0.31Mar '25Jun 2025: -$0.34Jun '25Sep 2025: -$0.30Sep '25Dec 2025: -$0.27Dec '25Mar 2026: -$0.29Mar '26Jun 2026: -$0.32Jun '26Sep 2026: -$0.32Sep '26Latest -$0.32
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How DSGN moved after its last 8 reports
Average move the session after a report ±7.5%
Nov 4, 2026After the close−9.0%
Aug 3, 2026Time not announced+4.8%
Apr 28, 2026After the close+23.3%
Mar 9, 2026After the close−3.7%
Nov 5, 2025After the close+4.9%
Aug 7, 2025After the close+7.8%
May 7, 2025After the close+5.7%
Mar 10, 2025Time not announced−1.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DSGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DSGN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DSGN

Technical Analysis

DSGN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 14% below its 20 day and 24% below its 50 day average. It is 35% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $8.80, and the nearest resistance the Pivot at $9.18.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.0%/day
Key levels
$17.2552 week high+91.2%
$12.64100 day average+40.1%
$12.17200 day average+34.9%
$11.1450 day average+23.5%
$11.00Swing high (Nov 11)+22.0%
$10.2820 day average+14.0%
$9.41Pivot R1+4.3%
$9.18Pivot+1.8%
$9.02Last close
$8.80Pivot S1−2.4%
$7.8152 week low−13.4%
Indicators
RSI (14)32.82Weak, oversold below 30Neutral
MACD-0.49Below its signal lineBearish
Stochastic3.8Near the bottom of its rangeOversold
ADX (14)19.3No clear trend
Williams %R-97.1Oversold below −80, overbought above −20Oversold
CCI (20)-193.8Oversold below −100, overbought above 100Oversold
Rate of change−11.7%Change over 10 sessionsBearish
ATR (14)$0.63Typical daily range, 7.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DSGN

What happened before

See how DSGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DSGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DSGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DSGNHow many large options trades hit DSGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

DSGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲81 buying vs 49 selling
  • ▲Held by funds +3.6 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding142138+2.9%
In funds' top 1034−25.0%
Held by funds83.2%79.6%+3.6 pts
New / increased16 / 6528 / 61−9.0%
Reduced / sold out36 / 1332 / 16+2.1%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DSGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DSGN Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 13, 2025Arsani WilliamDirectorSale562,627$5.25$3.0M
Dec 18, 2024Deepa PrasadDirectorSale3,806$6.27$24K
Every insider buy and sale for DSGN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DSGN insider trades →

From SEC Form 4 filings by DSGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DSGN is in one of them and how their past DSGN trades turned out.

DSGN in the AI portfolios
Loading…

DSGN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DSGN in an article yet. Here's the latest on the wider market.

DSGN in the news

About Design Therapeutics

Design Therapeutics is a biopharmaceutical company based in Carlsbad, California, that researches and develops GeneTAC molecules, a type of small molecule. These molecules are designed to target repeated DNA sequences that cause certain inherited diseases, and to adjust how genes are expressed in affected cells. The company's lead candidates are aimed at Friedreich ataxia, Fuchs endothelial corneal dystrophy and myotonic dystrophy type 1. Its candidates are still in development and are intended for patients with these inherited conditions.

Headquarters
Carlsbad, CA